A recent study tested a new daily tablet called orforglipron. It helped people with type‑2 diabetes lose weight and control their blood sugar better than the pills that are used today.
Why a new pill matters
For a few years, many people have used an injectable drug called semaglutide. It works like a natural gut hormone that tells the brain you are full. The injection can lower blood sugar and help people lose weight.
However, the injection has two big problems. First, you must use a needle, which many people dislike. Second, the medicine needs to stay cold, making it hard to ship to places without reliable refrigeration.
Because of these issues, scientists tried to make a pill version of the same drug. An oral form of semaglutide does exist, but it must be taken on an empty stomach and you have to wait 30 minutes before eating. Also, only about 1 % of the pill is actually absorbed, making it expensive to produce.
The new oral pill
In a large 52‑week trial, 1,698 adults with type‑2 diabetes from six countries took either the new tablet or the current oral semaglutide. The main goal was to see how much each drug could lower HbA1c, a blood test that shows average sugar levels over three months.
At the start, participants had an average HbA1c of 8.3 %. After a year, the group taking orforglipron lowered their HbA1c by 1.71‑1.91 %, while the semaglutide group lowered it by only 1.47 %.
People on the new pill also lost more weight. On average they dropped 6.1‑8.2 kg, compared with 5.3 kg in the semaglutide group.
Side effects
Like other drugs that act on the GLP‑1 pathway, orforglipron caused stomach problems for many users. About 59 % reported nausea, vomiting, diarrhea, or constipation, versus 37‑45 % for semaglutide.
Because the pill creates a higher peak level in the blood each day, more people stopped taking it. Roughly 10 % of the orforglipron group quit because of side effects, compared with 4‑5 % for semaglutide.
What makes it different?
Orforglipron belongs to a class called small‑molecule drugs. These are tiny chemical compounds that can be absorbed straight through the gut wall and still activate GLP‑1 receptors.
Semaglutide, on the other hand, is a peptide drug. Its structure looks a lot like the natural hormone, which makes it harder and more expensive to manufacture.
Small‑molecule drugs are cheaper to make and do not need refrigeration. This could help bring the medicine to low‑ and middle‑income countries where keeping drugs cold is difficult.
Looking ahead
The study shows orforglipron works well for blood‑sugar control and weight loss. However, its higher rate of stomach upset may limit how many people keep using it.
The pill is still being tested in people who are overweight but do not have diabetes. Future research will show whether it can become a popular, affordable option worldwide.
